VivoSeq
Other

Metabolic Disease

27

Pipeline Programs↗

3

Active Trials↗

16

Companies Involved↗

Metabolic Disease is an emerging landscape with 27 programs across 16 companies. The most active players are Neurim Pharmaceuticals Ltd., Ipsen, Novartis. 8 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

71/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Neurim Pharmaceuticals Ltd.

1 program

Phase 1Ipsen logo

Ipsen

1 program

Phase 1Novartis logo

Novartis

2 programs

Phase 2Pfizer logo

Pfizer

1 program

Phase 2Akero Therapeutics logo

Akero Therapeutics

1 program

Phase 2V

Viking Therapeutics, Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

24 of 27 classified programs — the dominant modality here.

11%ALL OTHERSPeptide27%Protein / enzyme14%

Small molecule leads; the ring shows all 27 classified programs, each share of the total. Modality classified for 100% of 28 pipeline programs.

Analysis

Trial Status

13

clinical trials

Completed5 · 38%
Recruiting3 · 23%
Unknown status3 · 23%
Withdrawn1 · 8%
Terminated1 · 8%

Clinical Trials

Trial Activity

13 trials

UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
Recruiting·JJoanne Kurtzberg, MD·Phase 1·NCT02254863·40 enrolled
The Natural History, Physiology, Microbiome and Biochemistry Studies of Propionic Acidemia
Recruiting·NNational Human Genome Research Institute (NHGRI)·N/A·NCT02890342·1,045 enrolled
Cardiovascular Disease Discovery Protocol
Recruiting·National Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT01143454·5,000 enrolled
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases
Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003662·90 enrolled
A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases
Completed·—·Phase 1·NCT01340911·78 enrolled
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
Completed·FFundacion SEIMC-GESIDA·Phase 4·NCT05898841·63 enrolled
Long-term Effect of Steroid on Metabolic Diseases in Asthmatics
Completed·—·N/A·NCT06279078·19,968 enrolled
Human Translational Studies of Inflammation and Cardiometabolic Diseases: The Psoriasis, Atherosclerosis and Cardiometabolic Disease (PACI) Initiative
Completed·National Heart, Lung, and Blood Institute (NHLBI)·N/A·NCT01778569·386 enrolled
Effects of IGF-I in HIV Metabolic Disease
Terminated·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT01329744·16 enrolled
The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.
Withdrawn·CCorEvitas·N/A·NCT06354101
Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes
Unknown status·YYonsei University·N/A·NCT03204799·150 enrolled
Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
Unknown status·RRoyal College of Surgeons, Ireland·N/A·NCT05773183·60 enrolled
Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk
Unknown status·—·Phase 2·NCT03113994·8 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)